Kiora Pharmaceuticals Inc (KPRX) stock
Close on Nov 12, 2026Market cap $5.88MP/E –Yield –
Kiora Pharmaceuticals Inc saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$7.90M. At the latest close the market valued the company at $5.88M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $5.88M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.38
- Dividend yield
- –
- Free cash flow yield
- -134.22%
Fundamentals
- Revenue
- $0
- Net income
- -$12.76M
- EPS, diluted
- -$2.86
- Free cash flow
- -$7.90M
- Book value per share
- $2.43
- Diluted shares
- 6M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.35
- Open
- $1.33
- Day's range
- $1.33 – $1.39
- Volume
- 20,640
- Average volume (20 days)
- 64,624
- Beta (5 years)
- 0.82
- 52-week range
- $1.33 – $2.91
- RSI (14 days)
- 22.8
- Volatility (1 year)
- 64.3%
- Relative volume
- 0.75×
- WACC
- 9.0%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KPRX | S&P 500 | Difference | KPRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -48.0% | -2.7% | −45.4 pts | ||
| 3 months | -49.6% | -1.7% | −47.9 pts | ||
| Year to date | -32.5% | +11.9% | −44.4 pts | ||
| 1 year | -42.3% | +12.0% | −54.3 pts | ||
| 3 years | -76.7% | +78.2% | −154.9 pts | -38.4% | +21.2% |
| 5 years | -99.8% | +73.2% | −173.0 pts | -69.8% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -58.0% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kiora Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Kiora Pharmaceuticals
Pharmaceutical Preparations
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for retinal diseases. Its primary product candidates include KIO-301, a small-molecule photoswitch designed to restore light sensitivity in patients suffering from inherited and age-related retinal degenerations like retinitis pigmentosa, and KIO-104, a dihydroorotate dehydrogenase inhibitor formulated for intravitreal injection to treat retinal inflammatory conditions such as diabetic macular edema and posterior non-infectious uveitis. The company also maintains KIO-101, a topical eye drop formulation aimed at addressing ocular manifestations of autoimmune disorders. Its prospective end users encompass individuals experiencing severe or degenerative vision impairments.
Company profile, executives and historyKiora Pharmaceuticals stock: common questions
What is Kiora Pharmaceuticals's stock price?
KPRX closed at $1.33 on Nov 12, 2026, down 1.48% on the day. Over the past 52 weeks it traded between $1.33 and $2.91.
What is Kiora Pharmaceuticals's market cap?
Kiora Pharmaceuticals was worth $5.88M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KPRX's P/E ratio?
Kiora Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.86), so it has no meaningful P/E ratio.
How much revenue does Kiora Pharmaceuticals make?
Kiora Pharmaceuticals reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Kiora Pharmaceuticals pay a dividend?
No. Kiora Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Kiora Pharmaceuticals report earnings next?
Kiora Pharmaceuticals's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has KPRX stock performed over the past year?
Including dividends, KPRX returned -42.3% over the past year, against +12.0% for the S&P 500.
Who are Kiora Pharmaceuticals's competitors?
Companies most similar to Kiora Pharmaceuticals by business, industry and size include KZIA, ADXN, JUNS, IFRX, PRFX.
See a number that looks wrong?